Scienture Holdings Inc(SCNX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.81 | Insider Own | 23.92% | Shs Outstand | 41.1M | Perf Week | -14% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 100% | Insider Trans | - | Shs Float | 31.2M | Perf Month | -36.6% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.06 | Inst Own | 5.3% | Short Float | 3.27% | Perf Quarter | -25.35% |
| Income | -0.02B | P/S | 18.01 | EPS this Y | 91.48% | Inst Trans | 5.31% | Short Ratio | 0.4 | Perf Half Y | -41.18% |
| Sales | 0.00B | P/B | 0.18 | EPS next 5Y | - | ROA | -20.29% | Short Interest | 1.02M | Perf YTD | -44.1% |
| Book/sh | 1.56 | P/C | 1.43 | EPS past 3/5Y | 23.94% 11.34% | ROE | -24.07% | 52W High | -89.03% ($2.60) | Perf Year | -67.01% |
| Cash/sh | 0.2 | P/FCF | - | Sales past 3/5Y | -65.21% -52.1% | ROIC | -27.9% | 52W Low | 19.69% ($0.24) | Perf 3Y | -93.2% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 92.38% | Gross Margin | 82.75% | Volatility(W/M) | 8.53% 7.52% | Perf 5Y | -99.41% |
| Dividend TTM | - | EV/Sales | 21.85 | Sales Y/Y TTM | -73.18% | Oper. Margin | -2648.49% | ATR (14) | 0.03 | Perf 10Y | -99.27% |
| Dividend Ex-Date | - | Quick Ratio | 2.97 | EPS Q/Q | 78.1% | Profit Margin | -3145.84% | RSI (14) | 22.28 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.04 | Sales Q/Q | 3249.96% | SMA20 | -19.62% ($0.36) | Beta | 3.26 | Target Price | $1.5 |
| Payout | - | Debt/Eq | 0.17 | Earnings | 2026/8/14 | SMA50 | -26.56% ($0.39) | Rel Volume | 6.39 | Prev Close | $0.3 |
| Employees | 9 | LT Debt/Eq | 0.15 | EPS/Sales Surpr. | 22.22% - | SMA200 | -32.34% ($0.43) | Avg Volume(3M) | 2.55M | Price | $0.29 |
| IPO | 2009/1/26 | Option/Short | No/Yes | Trades | 11388 | Volume | 16,303,206 | Change | -6.43% |
Company
SCNX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 ScienHoldings () is a small publicly listed company that has transformed into a specialty pharmaceutical company focused on commercializing 505(b)(2)-based specialty drugs, after divesting its legacy healthcare IT and wholesale businesses. Its flagship products include FDA-approved losartan oral suspension Arbli™ and the nasal spray formulation of naloxone, REZENOPY™, licensed from Kindeva/Summit, and the company is currently working to penetrate the cardiovascular and central nervous system markets.
Over the past 1 year, on the lower side
89% below its 1-year high.
SCNX has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +91.5% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -93.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 5.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VTI 0.00%
VXF 0.00%It ranks #3 in the industry
Based on market cap of $12M.
SCNX $12M PER -
HITI $246M PER -
PETS $34M PER -
POM $5M PER -
FAQ
What kind of company is SCNX?
SCNX belongs to the Healthcare sector and operates in the Pharmaceutical Retailers industry.
What is the market cap of SCNX?
The market cap of SCNX is approximately $12M, ranking 5,448 within its sector.
What is the 52-week high and low for SCNX?
SCNX has recorded a 52-week high of $2.60 and a low of $0.24.
